( 10.1016/S2213-8587(1500436-2) [DOI] [PubMed] [Google Scholar] 60.Johansen NJ, Dejgaard TF, Lund A, Schlntz C, Frandsen CS, Forman JL, Wewer Albrechtsen NJ, Holst JJ, Pedersen-Bjergaard U, Madsbad Set al
See how the Bridge compares to other GLP-1 options: Wegovy vs
Why Patients Stop Discontinuation Rates by Cause Reported nausea and stopping treatment because of it are very different figures
These arise because GLP1 agonists slow stomach emptying and intensify satiety signals, which can leave you feeling uncomfortably full after small meals and trigger food aversions
Overweight and obesity are associated with increased risk of infertility including an increased time to pregnancy, ovulatory dysfunction, and when using assisted reproductive technology, a lower chance of pregnancy success (Van Der Steeg et al
Viljoen, A